TRDA — Entrada Therapeutics Share News
0.000.00%
Last trade - 00:00- $171.71m
- -$51.29m
- $25.42m
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview
Entrada sinks after Duchenne drug underwhelms in early trial
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
Entrada sinks after Duchenne drug underwhelms in early trial
Entrada shares sink after Duchenne drug falls short of expectations (updated)
Entrada Therapeutics Q1 net loss beats analyst estimates
Entrada's Duchenne drug shown to improve muscle function in early trial
Entrada Therapeutics Q4 net loss and EPS beat expectations
Brief: Entrada Therapeutics Inc On Track To Report Elevate-44-201 Cohort 1 Data In Q2 2026, Cohort 2 Data By End Of Year
Brief: Entrada Therapeutics may issue up to $400 million in securities - SEC filing
Entrada Therapeutics Q3 net loss widens to $44.1 mln
Brief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics Q2 collaboration revenue drops, net loss widens
Brief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Entrada Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary